Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-EARLY OLE: Acoramidis in Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy
NCT07116473Phase 3Not yet recruiting
- Sponsor
- BridgeBio Pharma
- Start
- Nov 2026
- Primary completion
- Nov 2037
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by BridgeBio Pharma. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
acoramidis
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT07116473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07116473.